Zevalin Y-90 and Hematological toxicity
Result of checking the interaction of drug Zevalin Y-90 and disease Hematological toxicity for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies. Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan. It is recommended to monitor patients for hematological toxicity including development of MDS or AML.
Generic Name: ibritumomab
Brand Name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Y-90 Zevalin
Zevalin Y-90 - toksyczność hematologiczna 
Zevalin Y-90 - toxicidade hematológica 
Zevalin Y-90 - ketoksikan hematologi 
Zevalin Y-90 - toksisitas hematologis 
Zevalin Y-90 - tossicità ematologica 
Zevalin Y-90 - toxicité hématologique 
Zevalin Y-90 - hämatologische Toxizität 
Zevalin Y-90 - toxicidad hematológica 
Zevalin Y-90 - гематологическая токсичность 
Zevalin Y-90 - hematolojik toksisite 
Zevalin Y-90 - سمية دموية 
Zevalin Y-90 - 血液学毒性